Glioblastoma News and Research RSS Feed - Glioblastoma News and Research

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Combined MRI and ultramicroscopy toolkit could help study vessel growth in glioma models in more detail

Combined MRI and ultramicroscopy toolkit could help study vessel growth in glioma models in more detail

Stopping the growth of blood vessels in tumours is a key target for glioblastoma therapies, and imaging methods are essential for initial diagnosis and monitoring the effects of treatments. While mapping vessels in tumours has proven a challenge, researchers have now developed a combined magnetic resonance imaging (MRI) and ultramicroscopy 'toolkit' to study vessel growth in glioma models in more detail than previously possible. [More]
Study provides detailed new information about diffuse glioma

Study provides detailed new information about diffuse glioma

An international collaborative study has revealed detailed new information about diffuse glioma, the most common type of tumor found in some 80 percent of adult brain cancer patients, raising hopes that better understanding of these disease groups may aid improved clinical outcomes. [More]
Researchers reveal totally new biological mechanism that underlies cancer

Researchers reveal totally new biological mechanism that underlies cancer

In a landmark study, researchers from the Broad Institute and Massachusetts General Hospital reveal a completely new biological mechanism that underlies cancer. By studying brain tumors that carry mutations in the isocitrate dehydrogenase (IDH) genes, the team uncovered some unusual changes in the instructions for how the genome folds up on itself. [More]
Salk Institute scientists find new target for glioblastoma multiforme treatment

Salk Institute scientists find new target for glioblastoma multiforme treatment

Glioblastoma multiforme is a particularly deadly cancer. A person diagnosed with this type of brain tumor typically survives 15 months, if given the best care. The late Senator Ted Kennedy succumbed to this disease in just over a year. [More]
Researchers reveal specific enzyme responsible for sensing energy source that fuels growth of cancer cells

Researchers reveal specific enzyme responsible for sensing energy source that fuels growth of cancer cells

An international research team formed by a University of Cincinnati cancer researcher has shown for the first time that a specific enzyme is responsible for sensing the available supply of GTP, an energy source that fuels the uncontrolled growth of cancer cells. The research underscores the enzyme's potential to become a therapeutic target for future cancer drugs. [More]
Northwest Biotherapeutics closes registered direct placement of $12.6M

Northwest Biotherapeutics closes registered direct placement of $12.6M

Northwest Biotherapeutics, a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of its previously-announced registered direct placement with healthcare focused institutional investors, for gross proceeds of $12.6 million on the terms previously announced. [More]
Drugs approved for various conditions also have antibiotic properties

Drugs approved for various conditions also have antibiotic properties

A number of drugs already approved to treat parasitic infections, cancers, infertility and other conditions also show promise as antibiotic agents against staph and tuberculosis infections, according to a new study by University of Illinois chemists and collaborators. Because these agents act against multiple targets within the bacteria, it may be harder for bacteria to develop resistance. [More]
Researchers outline novel molecular interactions affecting key cancer pathway in humans

Researchers outline novel molecular interactions affecting key cancer pathway in humans

Researchers from the Cancer Science Institute of Singapore at the National University of Singapore have delineated novel molecular interactions affecting the activity of the TGF-β pathway, a key cancer pathway in humans affecting cancer progression. [More]
Use of tumor-treating fields along with chemotherapy improves survival in patients with brain tumor

Use of tumor-treating fields along with chemotherapy improves survival in patients with brain tumor

Early research indicates that the use of tumor-treating fields, a type of electromagnetic field therapy, along with chemotherapy in patients with a brain tumor who had completed standard chemoradiation resulted in prolonged progression-free and overall survival, according to a study in the December 15 issue of JAMA. [More]
ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

ImmunoCellular partners with CBTC for ICT-107 phase 3 registrational trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with a major Canadian cancer cooperative group, The Canadian Brain Tumour Consortium, for the phase 3 registrational trial of its cancer immunotherapy ICT-107 in patients with newly diagnosed glioblastoma. [More]
New nanocarriers may effectively deliver therapeutic drug to GBM tumors

New nanocarriers may effectively deliver therapeutic drug to GBM tumors

Glioblastoma multiforme, a cancer of the brain also known as "octopus tumors" because of the manner in which the cancer cells extend their tendrils into surrounding tissue, is virtually inoperable, resistant to therapies, and always fatal, usually within 15 months of onset. [More]
Scientists identify way to sensitize drug-resistant glioblastoma cells to chemotherapy

Scientists identify way to sensitize drug-resistant glioblastoma cells to chemotherapy

Scientists from the Virginia Tech Carilion Research Institute and clinicians from Carilion Clinic have discovered how to sensitize drug-resistant human glioblastoma cells to chemotherapy. [More]
TGen: PPF drug could help treat patients with deadly brain cancer

TGen: PPF drug could help treat patients with deadly brain cancer

In a significant breakthrough, the Translational Genomics Research Institute has identified a drug, propentofylline or PPF, that could help treat patients with deadly brain cancer. [More]
Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios announces data from dose-escalation phase 1 study of AG-120 in patients with IDH1 mutant positive advanced solid tumors

Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the first data from the dose-escalation portion of the ongoing Phase 1 study evaluating single agent AG-120, a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-1 (IDH1), in advanced solid tumors. The data are being presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. AG-120 is being developed in collaboration with Celgene. [More]
JEDI T-cells provide unique technology to study, visualize immune responses and immunotherapies

JEDI T-cells provide unique technology to study, visualize immune responses and immunotherapies

When it comes to fending off disease and helping prevent people from falling ill, the body's immune system -- armed with T-cells that help eliminate cancer cells, virus-infected cells and more -- is second to none. But exactly how the immune system works remains, in many ways, a mystery, as there are numerous cell types whose functions and interactions with our immune systems have not been well understood. [More]
UCSD researchers develop new computational strategy to find tumor-shrinking molecules

UCSD researchers develop new computational strategy to find tumor-shrinking molecules

Patients with glioblastoma, a type of malignant brain tumor, usually survive fewer than 15 months following diagnosis. Since there are no effective treatments for the deadly disease, University of California, San Diego researchers developed a new computational strategy to search for molecules that could be developed into glioblastoma drugs. In mouse models of human glioblastoma, one molecule they found shrank the average tumor size by half. [More]
RNA profiles of tumor-educated platelets may diagnose cancer, identify potential therapeutic approaches

RNA profiles of tumor-educated platelets may diagnose cancer, identify potential therapeutic approaches

Analysis of tumor RNA carried in platelets - blood components best known for their role in clotting - may prove to be more useful than other "liquid biopsy" technologies for diagnosing cancer and determining its primary location and potential therapeutic approaches. [More]
Franziska Michor named recipient of NYSCF - Robertson Stem Cell Prize

Franziska Michor named recipient of NYSCF - Robertson Stem Cell Prize

The New York Stem Cell Foundation announced today that Franziska Michor, PhD, is the 2015 recipient of the NYSCF - Robertson Stem Cell Prize for her work pioneering new approaches to study the growth, spread, and treatment of cancer. Her laboratory fuses her passions in mathematics, molecular biology and patient care to investigate how cancers form and progress. [More]
DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

DelMar reports positive data from preclinical study of VAL-083 for treatment of ovarian cancer

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced that yesterday it presented positive preclinical data demonstrating the promising potential of its lead product candidate VAL-083 (dianhydrogalactitol) as a treatment for ovarian cancer. [More]
CWRU investigator receives $2.82 million NIH grant to make stealth bombs for brain cancer treatment

CWRU investigator receives $2.82 million NIH grant to make stealth bombs for brain cancer treatment

A Case Western Reserve University researcher has received a 5-year, $2.82 million National Institutes of Health grant to make, in essence, stealth bombs that slip past the brain's defenses to attack an incurable form of cancer. [More]
Advertisement
Advertisement